DTIL Precision BioSciences |
$4.52
+1.6% |
-7.8%
 |
ARCUS
Eliminate DNA of living cells and organisms.
|
|
7/16/2025 - Additional data
Precision BioSciences, Inc announced updated additional preclinical data further validating the sci…
Full Summary
|
CUE Cue Biopharma |
$0.86
+22.3% |
+47.6%
 |
CUE-101
HPV+ recurrent/metastatic head and neck cancer
|
|
7/16/2025 - Clinical Update
Cue Biopharma, Inc. today provided a clinical update on its most advanced asset, CUE-101, represent…
Full Summary
|
VYGR Voyager Therapeutics |
$3.27
+6.2% |
+4.8%
 |
VY7523
In Alzheimer's Disease
|
|
7/16/2025 - Provided Update
Voyager Therapeutics, today continued the expansion of its Alzheimer's disease (AD) franchise with …
Full Summary
|
BCDA BioCardia |
$2.26
-0.9% |
+7.1%
 |
CardiAMP
Designed to be a comprehensive biotherapeutic heart failure solution
|
|
7/16/2025 - Enrollment Update
BioCardia, announced that Henry Ford Health in Detroit, Michigan is now enrolling patients with isc…
Full Summary
|
CGTX Cognition Therapeutics |
$0.62
+8.6% |
+120.2%
 |
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
|
Phase 2
|
7/16/2025 - Results
Cognition Therapeutics, Inc., announced that James E. Galvin, MD, MPH will present results from th…
Full Summary
|
ONCY Oncolytics Biotech |
$1.25
+10.6% |
+87.1%
 |
Pelareorep
In Breast Cancer
|
|
7/16/2025 - Provided Update
Oncolytics Biotech® Inc summarized its biomarker and translational data for pelareorep, the Company'…
Full Summary
|
QNCX Quince Therapeutics |
$1.68
-2.9% |
+23.5%
 |
eDSP
For Treatment Of Rare Neurodegenerative Disease Ataxia-Telangiectasia
|
Phase 3
|
7/16/2025 - Enrollment Update
Quince Therapeutics, Inc. announced that the company has completed enrollment in its pivotal Phase…
Full Summary
|
ADAG Adagene |
$1.97
+3.7% |
+2.6%
 |
ADG126
Advanced Solid Tumors
|
Phase 2
Target date: H2 2025
|
7/15/2025 - Enrollment Update
Adagene Inc. announced that Company expects to begin enrolling patients in Phase 2 in 2H 2025
Full Summary
|
INKT MiNK Therapeutics |
$23.11
-17.5% |
+208.5%
 |
AgenT-797
Multiple myeloma
|
|
7/15/2025 - Publication
MiNK Therapeutics, Inc. announced the publication of a peer-reviewed article titled "CAR-iNKT Cells:…
Full Summary
|
ABEO Abeona Therapeutics |
$6.26
+5.2% |
+4.3%
 |
ZEVASKYN
To Treat Wounds in Painful Skin Disorder
|
|
7/15/2025 - Provided Update
Abeona Therapeutics Inc. announced activation of the newest Qualified Treatment Center (QTC) for FD…
Full Summary
|
INBS Intelligent Bio Solutions |
$2.13
+12.1% |
+10.4%
 |
SMARTOX
in drug and alcohol screening services
|
|
7/15/2025 - Provided Update
Intelligent Bio Solutions Inc announced a new global distribution agreement with SMARTOX®, a Texas-…
Full Summary
|
LTRN Lantern Pharma |
$3.99
+6.1% |
+26.7%
 |
RADR
AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs).
|
|
7/15/2025 - Provided Update
Lantern Pharma Inc announced the launch of an innovative AI-powered module within its proprietary R…
Full Summary
|
APLS Apellis Pharmaceuticals |
$19.75
+2.1% |
+11.2%
 |
pegcetacoplan
Paroxysmal nocturnal hemoglobinuria (PNH)
|
|
7/15/2025 - Abstract Presentation
Apellis Pharmaceuticals, announced that five abstracts were accepted for oral presentation at the A…
Full Summary
|
PSTV Plus Therapeutics |
$0.32
+2.2% |
+5.0%
 |
REYOBIQ™
For Patients with Leptomeningeal Metastases
|
|
7/15/2025 - Oral presentation
Plus Therapeutics, Inc. announces the oral presentation of its ReSPECT-LM clinical trial results and…
Full Summary
|
NBIX Neurocrine Biosciences |
$133.48
+1.7% |
+6.9%
 |
CAHtalog
Patients With Classic Congenital Adrenal Hyperplasia In US
|
|
7/15/2025 - Results
Neurocrine Biosciences, Inc. announced results from a new analysis using real-world data from CAHt…
Full Summary
|
ADAG Adagene |
$1.97
+3.7% |
+2.6%
|
ADG126
Advanced Solid Tumors
|
FDA Type B Meeting
|
7/15/2025 - FDA Meeting
Adagene Inc. announced outcomes from its Type B meeting with the United States Food and Drug Adminis…
Full Summary
|
ATRC AtriCure |
$30.38
-0.5% |
-6.8%
 |
LeAAPS
For Stroke Prevention
|
|
7/15/2025 - Enrollment Completion
AtriCure, Inc announced the completion of enrollment in the left atrial appendage exclusion for prop…
Full Summary
|
SLS SELLAS Life Sciences Group |
$1.92
+1.1% |
+23.1%
 |
SLS009
For Treatment of Acute Myeloid Leukemia
|
Phase 2
|
7/15/2025 - Endpoint Met
SELLAS Life Sciences Group, Inc announced that is has met all primary endpoints in its Phase 2 tria…
Full Summary
|
KZR Kezar Life Sciences |
$4.50
-2.6% |
+10.0%
 |
zetomipzomib
In Patients with Autoimmune Hepatitis
|
Phase 2a
|
7/15/2025 - Lifted Clinical Hold
Kezar Life Sciences, Inc. announced that the Division of Hepatology and Nutrition of the U.S. Food…
Full Summary
|
AGEN Agenus |
$6.36
+2.3% |
+33.1%
 |
AgenT-797
Multiple myeloma
|
|
7/15/2025 - Publication
MiNK Therapeutics, Inc. announced the publication of a peer-reviewed article titled "CAR-iNKT Cells:…
Full Summary
|
DARE Dare Bioscience |
$2.62
-7.7% |
-9.8%
 |
Ovaprene
Intravaginal Contraceptive
|
Phase 3
|
7/14/2025 - Efficacy and Safety results
Daré Bioscience, Inc. announced positive interim safety and efficacy results from its ongoing Phase …
Full Summary
|
ABEO Abeona Therapeutics |
$6.26
+5.2% |
+4.3%
|
ZEVASKYN
To Treat Wounds in Painful Skin Disorder
|
|
7/14/2025 - Provided Update
Bio-Techne Corporation announced that its Simple Western™ Technology played a key role in supportin…
Full Summary
|
VRTX Vertex Pharmaceuticals |
$469.55
+1.2% |
+6.2%
 |
suzetrigine
For the Treatment of Moderate-to-Severe Acute Pain
|
|
7/14/2025 - Provided Update
Vertex Pharmaceuticals Incorporated announced that it has been named a 2025 Breakthroughs Innovatio…
Full Summary
|
AZN AstraZeneca |
$70.08
-0.3% |
-1.3%
 |
BaxHTN
In patients with uncontrolled or treatment resistant hypertension
|
Phase 3
|
7/14/2025 - Positive Results
AstraZeneca announced Positive high-level results from the BaxHTN Phase III trial showed baxdrostat …
Full Summary
|
TAK Takeda Pharmaceutical |
$14.72
-0.2% |
-1.2%
 |
TAK-861
In patients with moderate to severe obstructive sleep apnea undergoing general anesthesia.
|
Phase 3
|
7/14/2025 - Endpoint Met
Takeda announced that all primary and secondary endpoints were met in two Phase 3 randomized, double…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$27.31
+0.4% |
-25.5%
 |
evinacumab
With Homozygous Familial Hypercholesterolemia (HoFH)
|
|
7/14/2025 - Provided Update
Ultragenyx Pharmaceutical Inc. announced that Health Canada has extended the approval of Evkeeza® (…
Full Summary
|
RANI Rani Therapeutics |
$0.41
-3.9% |
-20.2%
 |
RaniPill
For the treatment of obesity
|
|
7/14/2025 - Data Presentation
Rani Therapeutics Holdings, Inc announced that it will present preclinical data on the RaniPill® ca…
Full Summary
|
NBIX Neurocrine Biosciences |
$133.48
+1.7% |
+6.9%
|
crinecerfont
For the Treatment of Congenital Adrenal Hyperplasia (CAH)
|
|
7/14/2025 - Presentation
Neurocrine Biosciences, announced the presentation of new one-year data from the CAHtalyst™ Adult s…
Full Summary
|
NBIX Neurocrine Biosciences |
$133.48
+1.7% |
+6.9%
|
CAHtalyst™
For the Treatment of Congenital Adrenal Hyperplasia
|
|
7/14/2025 - Data Presentation
Neurocrine Biosciences, Inc. announced the presentation of new data from the Phase 3 CAHtalyst™ Adu…
Full Summary
|
CORT Corcept Therapeutics |
$72.85
+2.0% |
+1.4%
 |
Relacorilant
Recurrent Platinum-Resistant Ovarian Cancer
|
NDA
|
7/14/2025 - NDA Filing
Corcept Therapeutics Incorporated announced that it has submitted a new drug application (NDA) to t…
Full Summary
|
ASND Ascendis Pharma A/S |
$175.40
+0.4% |
+1.4%
 |
TransCon PTH
Adult Hypoparathyroidism
|
Phase 3
|
7/14/2025 - New Data
Ascendis Pharma announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long…
Full Summary
|
GILD Gilead Sciences |
$109.85
+0.7% |
+1.7%
 |
Yeztugo
For HIV Prevention
|
|
7/14/2025 - Data Presentation
Gilead Sciences, Inc announced that Gilead researchers and collaborators will present new Phase 3 P…
Full Summary
|
MRK Merck & Co., Inc. |
$82.45
+1.1% |
+5.2%
 |
MK-8527
novel nucleoside reverse transcriptase translocation inhibitor
|
Phase 3
|
7/14/2025 - Clinical Trial
Merck announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and …
Full Summary
|
CRNX Crinetics Pharmaceuticals |
$31.90
+0.2% |
+3.4%
 |
Paltusotine
Acromegaly
|
|
7/13/2025 - New Data
Crinetics Pharmaceuticals, Inc. announced new data from its clinical development program evaluating …
Full Summary
|
RYTM Rhythm Pharmaceuticals |
$91.44
+2.3% |
+47.6%
 |
Setmelanotide (HO)
Hypothalamic Obesity
|
|
7/12/2025 - Data
Rhythm Pharmaceuticals, Inc. announced data from three new presentations on the Company's clinical …
Full Summary
|
INKT MiNK Therapeutics |
$23.11
-17.5% |
+208.5%
|
AgenT-797
Multiple myeloma
|
|
7/11/2025 - Publication
MiNK Therapeutics, Inc. announced the publication of another landmark case in Nature's Oncogene des…
Full Summary
|
CAPR Capricor Therapeutics |
$7.24
+0.8% |
-40.6%
 |
deramiocel
For the treatment of Duchenne muscular dystrophy (DMD)
|
BLA
|
7/11/2025 - Complete Response Letter
Capricor Therapeutics announced that it has received a Complete Response Letter (CRL) from the U.S.…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.87
+12.7% |
+46.1%
 |
SKNY-1
For Obesity
|
|
7/11/2025 - Results
MIRA Pharmaceuticals, Inc. announced new preclinical results from SKNY-1, an oral drug candidate fo…
Full Summary
|
VSTM Verastem |
$5.25
+7.4% |
-1.1%
 |
RAMP 201
Vutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).
|
Phase 2
|
7/11/2025 - Analysis
Verastem Oncology announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was p…
Full Summary
|
MIST Milestone Pharmaceuticals |
$1.67
+12.8% |
-3.5%
 |
Etripamil
For Treatment in Paroxysmal Supraventricular Tachycardia
|
|
7/11/2025 - FDA review
Milestone® Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has acce…
Full Summary
|
AGEN Agenus |
$6.36
+2.3% |
+33.1%
|
AgenT-797
Multiple myeloma
|
|
7/11/2025 - Publication
MiNK Therapeutics, Inc. announced the publication of another landmark case in Nature's Oncogene des…
Full Summary
|
MIST Milestone Pharmaceuticals |
$1.67
+12.8% |
-3.5%
|
Etripamil
For Treatment in Paroxysmal Supraventricular Tachycardia
|
Target date: December 13, 2025
|
7/11/2025 - PDUFA Date
Milestone® Pharmaceuticals Inc announced that The FDA has assigned a new Prescription Drug User Fee…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$27.31
+0.4% |
-25.5%
|
UX111
For Sanfilippo syndrome type A (MPS IIIA)
|
BLA
|
7/11/2025 - Complete Response Letter
Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has issued a Co…
Full Summary
|
ABOS Acumen Pharmaceuticals |
$1.38
+5.3% |
+13.1%
 |
Sabirnetug
for Early Alzheimer's Disease
|
|
7/10/2025 - Presentation
Acumen Pharmaceuticals, will present new findings at the upcoming Alzheimer's Association Internati…
Full Summary
|
ONC BeOne Medicines |
$279.16
+3.5% |
+9.9%
 |
Tislelizumab
Recurrent or Metastatic Nasopharyngeal Cancer
|
EC Approval
|
7/10/2025 - Approved
BeOne Medicines Ltd. announced that the European Commission has approved TEVIMBRA® (tislelizumab), i…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$45.06
+1.9% |
+29.0%
 |
TNX-801
Potential Vaccine to Prevent Mpox and Smallpox
|
|
7/10/2025 - Presentation
Tonix Pharmaceuticals announced the presentation of new findings on TNX-801 (recombinant horsepox,…
Full Summary
|
LGND Ligand Pharmaceuticals |
$129.63
+4.3% |
+15.2%
 |
ZELSUVMI
For the Treatment of Molluscum Contagiosum
|
|
7/10/2025 - Provided Update
Pelthos Therapeutics Inc. announced the launch of ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the…
Full Summary
|
PFE Pfizer |
$24.59
-0.1% |
+2.4%
 |
XTANDI (Enzalutamide)
Metastatic Hormone-Sensitive Prostate Cancer
|
Phase 3
|
7/10/2025 - Top-line results
Pfizer Inc. and Astellas Pharma Inc announced positive topline results from the overall survival (O…
Full Summary
|
MRK Merck & Co., Inc. |
$82.45
+1.1% |
+5.2%
|
Doravirine/Islatravir
In adults with HIV-1 infection
|
NDA
|
7/10/2025 - FDA review
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Dru…
Full Summary
|
STOK Stoke Therapeutics |
$11.90
+1.3% |
+2.1%
 |
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
Phase 3
|
7/10/2025 - Presentation
Stoke Therapeutics, Inc and Biogen Inc announced the presentation of data from an analysis that inf…
Full Summary
|
COCP Cocrystal Pharma |
$1.67
-2.0% |
+5.0%
 |
CDI-988
For Pandemic Norovirus and Coronavirus
|
|
7/10/2025 - Oral presentation
Cocrystal Pharma, Inc announces that its first-in-class pan-viral protease inhibitor CDI-988 has be…
Full Summary
|
RGNX REGENXBIO |
$8.50
+3.2% |
-1.8%
 |
RGX-202
Duchenne Muscular Dystrophy
|
|
7/10/2025 - Publication
REGENXBIO Inc. announced the publication of preclinical results comparing a microdystrophin gene the…
Full Summary
|
PDSB PDS Biotechnology |
$1.21
+3.4% |
-25.3%
 |
PDS01ADC
For the treatment of recurrent prostate cancer
|
|
7/10/2025 - Provided Update
PDS Biotechnology announced patient recruitment has been completed in Stage 1 of a clinical trial o…
Full Summary
|
AAPG Ascentage Pharma Group International |
$38.62
+5.1% |
+22.1%
 |
lisaftoclax
In Venetoclax-Refractory Patients
|
NMPA Approval
|
7/10/2025 - Approved
Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-25…
Full Summary
|
RCUS Arcus Biosciences |
$9.26
+2.6% |
+6.1%
 |
quemliclustat
For Pancreatic Cancer
|
Orphan Drug
|
7/10/2025 - Designation Grant
Arcus Biosciences, Inc announced that quemliclustat, an investigational small molecule CD73 inhibito…
Full Summary
|
CGTX Cognition Therapeutics |
$0.62
+8.6% |
+120.2%
|
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
|
Phase 2
|
7/10/2025 - FDA Meeting
Cognition Therapeutics, Inc., announced that it conducted an end-of-Phase 2 meeting with the U.S. F…
Full Summary
|
KRYS Krystal Biotech |
$150.08
+1.6% |
+15.4%
 |
KB801
For the Treatment of Neurotrophic Keratitis
|
Phase 1/2
|
7/9/2025 - Dose Update
Krystal Biotech, Inc announced that the first patient has been dosed in its Phase 1/2 clinical trial…
Full Summary
|
RZLT Rezolute |
$5.35
+4.7% |
+29.5%
 |
Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism
|
Phase 3
|
7/9/2025 - Abstract
Rezolute, Inc announced that the abstract titled "Preliminary Patient Demographics And Baseline Char…
Full Summary
|
EXAS Exact Sciences |
$53.67
+1.3% |
+2.2%
 |
Oncodetect™
Molecular Residual Disease Test
|
|
7/9/2025 - Provided Update
Exact Sciences Corp announced that its Oncodetect™ molecular residual disease (MRD) test has recei…
Full Summary
|
BIVI BioVie |
$7.31
+4.6% |
-29.0%
 |
Bezisterim
For Parkinson's Disease Patients
|
|
7/9/2025 - Provided Update
BioVie Inc. presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th Worl…
Full Summary
|
KZIA Novogen |
$10.19
-5.6% |
+9.2%
 |
Paxalisib
Atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer
|
Phase 1b
|
7/9/2025 - Preliminary Results
Kazia Therapeutics announce preliminary results from the first patient in its Phase 1b trial evalua…
Full Summary
|
BNTC Benitec Biopharma |
$11.75
-5.5% |
-23.9%
 |
BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)
|
Phase 1b/2a
|
7/9/2025 - Enrollment Update
Benitec Biopharma Inc. announced the recommendation of the independent Data Safety Monitoring Board…
Full Summary
|
EOLS Evolus |
$9.20
-0.8% |
-0.5%
 |
Nuceiva®
For the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2.
|
|
7/9/2025 - Provided Update
Evolus, Inc announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinu…
Full Summary
|
KALA KALA BIO |
$5.96
+9.0% |
+42.6%
 |
KPI-012
Clinical diagnosis of PCED
|
Target date: Q3 2025
|
7/9/2025 - Top-line results
KALA BIO, Inc. announced that Topline results from the CHASE trial expected by end of Q3 2025 --
Full Summary
|
MTVA MetaVia |
$0.67
+0.9% |
-2.6%
 |
DA-1726
For The Treatment Of Obesity
|
Target date: Q4 2025
|
7/9/2025 - Top-line data
MetaVia Inc. announced that Top-Line Data Expected in the Fourth Quarter of 2025
Full Summary
|
RYTM Rhythm Pharmaceuticals |
$91.44
+2.3% |
+47.6%
|
bivamelagon
In patients with acquired hypothalamic obesity.
|
Phase 2
|
7/9/2025 - Top-line results
Rhythm Pharmaceuticals, Inc. announced positive topline results from its Phase 2 trial evaluating bi…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$27.31
+0.4% |
-25.5%
|
UX143 (setrusumab)
Osteogenesis Imperfecta (OI)
|
Phase 3
|
7/9/2025 - evaluation
Ultragenyx Pharmaceutical announced that the randomized, placebo-controlled Phase 3 portion of the O…
Full Summary
|
CNTB Connect Biopharma |
$1.62
+11.0% |
+50.0%
 |
Rademikibart
For Moderate-To-Severe Atopic Dermatitis
|
NDA
|
7/9/2025 - NDA Filing
Connect Biopharma Holdings Limited announced that the Company's collaborator and exclusive licensee…
Full Summary
|
MTVA MetaVia |
$0.67
+0.9% |
-2.6%
|
DA-1726
For The Treatment Of Obesity
|
Phase 1
|
7/9/2025 - Dosing Update
MetaVia Inc. announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) coho…
Full Summary
|
LLY Eli Lilly and Company |
$788.91
+2.2% |
-0.3%
 |
Kisunla
For the Treatment of Early Symptomatic Alzheimer's Disease
|
|
7/9/2025 - FDA approved
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a la…
Full Summary
|
KALA KALA BIO |
$5.96
+9.0% |
+42.6%
|
KPI-012
Clinical diagnosis of PCED
|
|
7/9/2025 - Enrollment Completion
KALA BIO, Inc. announced the completion of patient enrollment in the CHASE (Corneal Healing After SE…
Full Summary
|
BHC Bausch Health Cos |
$6.44
+0.3% |
+12.4%
 |
CABTREO
For the Treatment of Acne Vulgaris
|
|
7/9/2025 - Provided Update
Bausch Health, Canada Inc announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl …
Full Summary
|
ALT Altimmune |
$4.18
|
-39.3%
 |
pemvidutide
for the treatment of obesity and MASH
|
Phase 2
|
7/9/2025 - Enrollment Update
Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase 2 trial evalua…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$45.06
+1.9% |
+29.0%
|
TNX-102 SL
Fibromyalgia
|
Phase 3
|
7/9/2025 - Results
Tonix Pharmaceuticals announced that full results from its confirmatory Phase 3 RESILIENT trial of …
Full Summary
|
ELAN Elanco Animal Health |
$14.51
-0.7% |
+6.6%
 |
TruCan™ Ultra
Canine Influenza Vaccine
|
|
7/9/2025 - Approved
Elanco Animal Health announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra …
Full Summary
|
BHC Bausch Health Cos |
$6.44
+0.3% |
+12.4%
|
PrCABTREOTM
For Treatment Of Acne Vulgaris
|
|
7/9/2025 - Provided Update
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. announced that PrCABTREOTM (clinda…
Full Summary
|
ASBP Aspire Biopharma |
$0.35
+10.1% |
+8.6%
 |
BUZZ BOMB
New Sublingual Pre-Workout Supplement
|
|
7/9/2025 - Positive Feedback
Aspire Biopharma Holdings, Inc. announced positive initial consumer feedback from the Company's samp…
Full Summary
|
ETON Eton Pharmaceuticals |
$13.89
-3.7% |
+2.1%
 |
ET-600
For the treatment of an endocrinology
|
NDA
|
7/8/2025 - FDA review
Eton Pharmaceuticals, Inc announced the Company's New Drug Application (NDA) for ET-600, a propriet…
Full Summary
|
UPB Upstream Bio |
$10.92
-2.0% |
+5.9%
 |
Verekitug
In Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2
|
7/8/2025 - Dose Update
Upstream Bio, Inc. announced that the first patient has been dosed in the Company's Phase 2 clinica…
Full Summary
|
SLDB Solid Biosciences |
$5.58
+3.5% |
+21.0%
 |
SGT-501
For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT)
|
IND
|
7/8/2025 - FDA Approval
Solid Biosciences Inc. announced approval of its Investigational New Drug (IND) application by the …
Full Summary
|
ETON Eton Pharmaceuticals |
$13.89
-3.7% |
+2.1%
|
ET-600
For the treatment of an endocrinology
|
NDA
Target date: February 25, 2026
|
7/8/2025 - PDUFA Date
Eton Pharmaceuticals, Inc announced that NDA has been assigned a Prescription Drug User Fee Act (…
Full Summary
|
ITCI Intra-Cellular Therapies |
$131.87
|
|
CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar
|
supplemental New Drug Application (sNDA)
|
7/8/2025 - sNDA Filing
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.…
Full Summary
|
LRMR Larimar Therapeutics |
$3.20
+1.3% |
+19.0%
 |
nomlabofusp
For Friedreich's Ataxia
|
|
7/8/2025 - Publication
Larimar Therapeutics, announced the publication of two peer-reviewed articles highlighting nonclin…
Full Summary
|
SLDB Solid Biosciences |
$5.58
+3.5% |
+21.0%
|
SGT-501
For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT)
|
Phase 1b
|
7/8/2025 - Clinical Trial
Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -
Full Summary
|
EPRX Eupraxia Pharmaceuticals |
$5.35
-0.6% |
+25.3%
 |
EP-104GI
For Treatment of Eosinophilic Esophagitis
|
Phase 2b
|
7/8/2025 - Dose Update
Eupraxia Pharmaceuticals Inc. announced the first patient dosed in the Phase 2b randomized, placebo-…
Full Summary
|
PSTV Plus Therapeutics |
$0.32
+2.2% |
+5.0%
|
REYOBIQ™
For Patients with Leptomeningeal Metastases
|
|
7/8/2025 - Provided Update
Plus Therapeutics, Inc. announced the treatment of its initial patients in the Company's ReSPECT-LM…
Full Summary
|
BCLI Brainstorm Cell Therapeutics |
$1.20
|
+0.8%
 |
NurOwn
Progressive Multiple Sclerosis (MS)
|
|
7/8/2025 - Provided Update
BrainStorm Cell Therapeutics Inc today acknowledged that the U.S. Food and Drug Administration's (F…
Full Summary
|
MRK Merck & Co., Inc. |
$82.45
+1.1% |
+5.2%
|
MK-8527
novel nucleoside reverse transcriptase translocation inhibitor
|
|
7/8/2025 - New Data
Merck announced that new data from its research pipeline for HIV prevention and treatment will be p…
Full Summary
|
JNJ Johnson & Johnson |
$164.78
+6.2% |
+8.1%
 |
CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar
|
supplemental New Drug Application (sNDA)
|
7/8/2025 - sNDA Filing
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.…
Full Summary
|
ARWR Arrowhead Pharmaceuticals |
$18.30
+3.8% |
+18.1%
 |
Zodasiran
For the Treatment of Homozygous Familial Hypercholesterolemia
|
Phase 3
|
7/8/2025 - Dose Update
Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first subject in the YOSEMITE Phase …
Full Summary
|
ONCY Oncolytics Biotech |
$1.25
+10.6% |
+87.1%
|
Pelareorep
In Breast Cancer
|
|
7/8/2025 - Clinical Data
Oncolytics Biotech® Inc announced a strategic update highlighting its compelling clinical data from…
Full Summary
|
RYTM Rhythm Pharmaceuticals |
$91.44
+2.3% |
+47.6%
|
bivamelagon
In patients with acquired hypothalamic obesity.
|
Phase 2
|
7/8/2025 - Provided Update
Rhythm Pharmaceuticals, Inc announced the Company will hold a conference call and webcast on Wednes…
Full Summary
|
MAT Mattel |
$19.60
+0.6% |
+4.0%
 |
Barbie
type 1 diabetes (T1D)
|
|
7/8/2025 - Provided Update
Mattel, Inc announced that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D).
Full Summary
|
OGN Organon & Co. |
$9.64
+0.8% |
-2.3%
 |
VTAMA (tapinarof) cream
Plaque psoriasis
|
|
7/7/2025 - Recommendation
Organon announced that VTAMA® (tapinarof) cream, 1%,was granted a strong recommendation by the Ameri…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$45.06
+1.9% |
+29.0%
|
TNX-801
Potential Vaccine to Prevent Mpox and Smallpox
|
|
7/7/2025 - Data Presentation
Tonix Pharmaceuticals announced that Sina Bavari, PhD, Executive Vice President of Infectious Diseas…
Full Summary
|
JSPR Jasper Therapeutics |
$3.35
+1.2% |
-38.1%
 |
Briquilimab
To address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU)
|
Phase 1b/2a
|
7/7/2025 - Updated data
Jasper Therapeutics is reporting updated data from Company's BEACON Phase 1b/2a study of subcutaneo…
Full Summary
|
MBIO Mustang Bio |
$2.21
-7.5% |
+116.7%
 |
MB-101
Leptomeningeal brain tumors
|
Orphan Drug
|
7/7/2025 - Designation Grant
Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr…
Full Summary
|
KALV KalVista Pharmaceuticals |
$15.79
+4.1% |
+30.0%
 |
sebetralstat
Therapy for hereditary angioedema (HAE).
|
|
7/7/2025 - FDA Approval
KalVista Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approv…
Full Summary
|
COGT Cogent Biosciences |
$11.86
+3.1% |
+55.6%
 |
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
|
7/7/2025 - Top-line results
Cogent Biosciences, Inc. announced positive top-line results from the registration-directed Part 2 …
Full Summary
|
URGN Urogen Pharma |
$14.34
+2.1% |
+8.3%
 |
UGN-103
For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
Phase 3
|
7/7/2025 - Enrollment Completion
UroGen Pharma Ltd. announced that it has completed patient enrollment in its Phase 3 UTOPIA clinica…
Full Summary
|
